A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

--"The 2025 forecast will command the most attention in the annual accounts," Hansen said. "The addition of production capacity will continue to be the guiding principle for the full-year forecast." ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...